Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.

Phase 1

Regeneron Pharmaceuticals

Rilonacept